Atacicept: targeting B cells in multiple sclerosis
Multiple sclerosis (MS) has traditionally been considered to be a T-cell-mediated disease. However, there is an increasing body of evidence for the involvement of B cells and autoantibodies in the pathology of this disease, providing a rationale for treatments directed against B cells. In this paper...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2010-07-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285610371146 |
_version_ | 1818554473332604928 |
---|---|
author | Hans-Peter Hartung Bernd C. Kieseier |
author_facet | Hans-Peter Hartung Bernd C. Kieseier |
author_sort | Hans-Peter Hartung |
collection | DOAJ |
description | Multiple sclerosis (MS) has traditionally been considered to be a T-cell-mediated disease. However, there is an increasing body of evidence for the involvement of B cells and autoantibodies in the pathology of this disease, providing a rationale for treatments directed against B cells. In this paper we summarize evidence for the key role of B cells in the immunopathology of MS and review data supporting the use of a novel B-cell targeted therapy, atacicept, in this condition. Atacicept is a human recombinant fusion protein that comprises the binding portion of a receptor for both BLyS (B-Lymphocyte Stimulator) and APRIL (A PRoliferation-Inducing Ligand), two cytokines that have been identified as important regulators of B-cell maturation, function and survival. Atacicept has shown selective effects on cells of the B-cell lineage, acting on mature B cells and blocking plasma cells and late stages of B-cell development while sparing B-cell progenitors and memory cells. The efficacy of atacicept in animal models of autoimmune disease and the biological activity of atacicept in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) has been demonstrated. Clinical studies were initiated to investigate the safety, tolerability and efficacy of atacicept in patients with MS. An unexpected increase in inflammatory activity in one of the trials, however, led to suspension of all atacicept trials in MS. |
first_indexed | 2024-12-12T09:39:57Z |
format | Article |
id | doaj.art-023750bdd4014f28a485d4a94bc3ab4f |
institution | Directory Open Access Journal |
issn | 1756-2856 |
language | English |
last_indexed | 2024-12-12T09:39:57Z |
publishDate | 2010-07-01 |
publisher | SAGE Publishing |
record_format | Article |
series | Therapeutic Advances in Neurological Disorders |
spelling | doaj.art-023750bdd4014f28a485d4a94bc3ab4f2022-12-22T00:28:34ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28562010-07-01310.1177/1756285610371146Atacicept: targeting B cells in multiple sclerosisHans-Peter HartungBernd C. KieseierMultiple sclerosis (MS) has traditionally been considered to be a T-cell-mediated disease. However, there is an increasing body of evidence for the involvement of B cells and autoantibodies in the pathology of this disease, providing a rationale for treatments directed against B cells. In this paper we summarize evidence for the key role of B cells in the immunopathology of MS and review data supporting the use of a novel B-cell targeted therapy, atacicept, in this condition. Atacicept is a human recombinant fusion protein that comprises the binding portion of a receptor for both BLyS (B-Lymphocyte Stimulator) and APRIL (A PRoliferation-Inducing Ligand), two cytokines that have been identified as important regulators of B-cell maturation, function and survival. Atacicept has shown selective effects on cells of the B-cell lineage, acting on mature B cells and blocking plasma cells and late stages of B-cell development while sparing B-cell progenitors and memory cells. The efficacy of atacicept in animal models of autoimmune disease and the biological activity of atacicept in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) has been demonstrated. Clinical studies were initiated to investigate the safety, tolerability and efficacy of atacicept in patients with MS. An unexpected increase in inflammatory activity in one of the trials, however, led to suspension of all atacicept trials in MS.https://doi.org/10.1177/1756285610371146 |
spellingShingle | Hans-Peter Hartung Bernd C. Kieseier Atacicept: targeting B cells in multiple sclerosis Therapeutic Advances in Neurological Disorders |
title | Atacicept: targeting B cells in multiple sclerosis |
title_full | Atacicept: targeting B cells in multiple sclerosis |
title_fullStr | Atacicept: targeting B cells in multiple sclerosis |
title_full_unstemmed | Atacicept: targeting B cells in multiple sclerosis |
title_short | Atacicept: targeting B cells in multiple sclerosis |
title_sort | atacicept targeting b cells in multiple sclerosis |
url | https://doi.org/10.1177/1756285610371146 |
work_keys_str_mv | AT hanspeterhartung atacicepttargetingbcellsinmultiplesclerosis AT berndckieseier atacicepttargetingbcellsinmultiplesclerosis |